Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus PROFENAL.
LODINE vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category C
Category C
NSAID
NSAID